Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD1 | O95696 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186964 | 0.87 | IMPDH2 (0.50) | SLC22A12IMPDH2GAAALDH1A1NPC1 | |
| SCHEMBL20186969 | 0.85 | IMPDH2 (0.48) | SLC22A12IMPDH2GAAALDH1A1NPC1 | |
| SCHEMBL20186979 | 0.85 | IMPDH2 (0.48) | SLC22A12IMPDH2GAAALDH1A1NPC1 | |
| SCHEMBL20186975 | 0.82 | IMPDH2 (0.48) | SLC22A12IMPDH2ALDH1A1 | |
| SCHEMBL31284484 | 0.81 | IMPDH2 (0.46) | SLC22A12IMPDH2GAAALDH1A1NPC1 | |
| SCHEMBL20186993 | 0.81 | IMPDH2 (0.46) | SLC22A12IMPDH2GAAALDH1A1NPC1 | |
| SCHEMBL20187004 | 0.81 | IMPDH2 (0.46) | SLC22A12IMPDH2GAAALDH1A1NPC1 | |
| SCHEMBL20186980 | 0.81 | SLC22A12 (0.54) | SLC22A12IMPDH2PLA2G7 | |
| SCHEMBL20186967 | 0.81 | IMPDH2 (0.45) | SLC22A12IMPDH2PLA2G7BRD4LMNA | |
| SCHEMBL2678340 | 0.76 | SLC22A12 (0.62) | SLC22A12GAABRD4BRD1BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905120-B2 | ABA receptor agonists that modulate transpiration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180146666-A1 | ABA RECEPTOR AGONISTS THAT MODULATE TRANSPIRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905120-B2 | ABA receptor agonists that modulate transpiration | ADORA2A, ADORA1, AAK1 | SLC22A12 930/4885IMPDH2 2394/4885GAA 1883/4885 |
| US-20180146666-A1 | ABA RECEPTOR AGONISTS THAT MODULATE TRANSPIRATION | ADORA2A, ADORA1, AAK1 | SLC22A12 930/4885IMPDH2 2394/4885GAA 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.